Latest news and press releases about Kamada Ltd. (KMDA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division.
Price
| Price | $8.19 |
| Market Cap | $473M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 20.76 |
| Price / Book | 1.71 |
| EV / EBITDA | 10.97 |
| Dividend Yield | 5.28% |
Profitability
| Return on Equity | 8.37% |
| Return on Invested Capital | 6.90% |
| Return on Assets | 5.81% |
| Gross Margin | 40.82% |
| Operating Margin | 14.51% |
| Net Margin | 11.60% |
Related companies: AUNA · EOLS · GALT · PRTC · QSI · RCKT · SLDB
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of KMDA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks